Treatment of Idiopathic Pulmonary Fibrosis (IPF) by REGEND007 Cell Therapy

Summary

This study is a prospective, single-arm, dose-escalation exploratory clinical trial to investigate the safety, tolerability and preliminary efficacy of REGEND007 stem cell preparation administered by intravenous infusion in the treatment of idiopathic pulmonary fibrosis (IPF), with a follow-up period of 12 weeks.

Timeline

Start

2026-02-15

Primary completion

2027-02-15

Completion

2027-06-15

Drugs

Indications